CVS CVS HEALTH Corp

CIK 0000064803 50 ready 8-Ks latest August 17, 2026, 4:19 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing August 17, 2026, 4:19 PM ET

Top materiality 0.85

Event mix earnings ×16 · debt ×11 · other_material ×10

Sentiment 12 pos · 8 neg · 30 neu

Latest earnings reported 2026-Q2

Executive change recent →

Recent 8-K filings for CVS

Highest-materiality recent filing

CVS Health Q4 revenue $105.7B (+8.2%); adj. EPS $1.09 vs $1.19; 2026 adj. EPS guide $7.00-$7.20

February 10, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Full-year 2025 revenue record $402.1B (+7.8%); GAAP EPS $1.39 (incl. $5.7B goodwill impairment), Adj. EPS $6.75 (+24.5%).
Q4 Health Care Benefits segment adj. op. loss ($676M) widened from ($439M) on IRA Medicare Part D seasonality.

Read filing →

August 17, 2026, 4:19 PM ET leadership materiality 0.50 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

CVS Health appoints Teresa Heitsenrether to board; Larry Robbins resigns

Larry Robbins resigned from CVS Health board effective Aug 13, 2026; no disagreement cited.
August 5, 2026, 6:32 AM ET earnings materiality 0.75 positive item 2.02 item 9.01

CVS Health Q2 2026 GAAP EPS $2.31, adj EPS $2.58; raises FY guidance to $7.90-$8.10 adj EPS

Total revenues $106.1B, up 7.3% YoY; GAAP diluted EPS $2.31 vs $0.80 prior year.
May 18, 2026, 4:13 PM ET other material materiality 0.25 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×5

CVS shareholders approve 2026 incentive plan, re-elect directors at annual meeting

13 directors elected; all management proposals passed including 2026 ICP approval.
May 6, 2026, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 9.01 ◈ Earnings Releases

CVS Q1 revenue $100.4B (+6.2% YoY); raises FY26 EPS guidance to $7.30-7.50

GAAP diluted EPS $2.30 vs $1.41 YoY; Adjusted EPS $2.57 vs $2.25 YoY.
March 19, 2026, 7:59 PM ET leadership materiality 0.35 neutral item 5.02

CVS Health elects former Elevance CFO John Gallina to board, effective March 19, 2026

John E. Gallina, age 66, former EVP and CFO of Elevance Health (NYSE: ELV), elected to CVS Health Board.
February 10, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

CVS Health Q4 revenue $105.7B (+8.2%); adj. EPS $1.09 vs $1.19; 2026 adj. EPS guide $7.00-$7.20

Full-year 2025 revenue record $402.1B (+7.8%); GAAP EPS $1.39 (incl. $5.7B goodwill impairment), Adj. EPS $6.75 (+24.5%).
December 9, 2025, 6:59 PM ET earnings materiality 0.75 positive item 7.01 item 9.01

CVS Health raises 2025 guidance and initiates 2026 outlook with mid-teens EPS CAGR target

2025 revenue guidance raised to at least $400B; Adjusted EPS raised to $6.60-$6.70 from $6.55-$6.65.
November 20, 2025, 6:59 PM ET leadership materiality 0.60 positive item 8.01 item 9.01

CVS Health appoints CEO David Joyner as Chair of the Board effective Jan 1, 2026

Joyner, President & CEO since Oct 2024, will also serve as Board Chair starting Jan 1, 2026.
October 29, 2025, 7:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01

CVS Health Q3 GAAP EPS loss of $3.13 on $5.7B goodwill impairment; raises FY2025 adjusted EPS guide to $6.55-$6.65

Total revenues of $102.9B, up 7.8% YoY; GAAP diluted loss per share of $3.13 includes $5.7B goodwill impairment charge.
September 22, 2025, 7:59 PM ET other material materiality 0.65 negative item 8.01 item 9.01

CVS subsidiary Omnicare files Chapter 11 bankruptcy after excessive court damages ruling

Omnicare, a wholly owned CVS subsidiary, voluntarily initiated Chapter 11 proceedings on Sept. 22, 2025.
August 15, 2025, 7:59 PM ET debt materiality 0.65 neutral item 8.01 item 9.01

CVS Health issues $4B in senior notes across four tranches with maturities 2032-2065

$750M 5.000% Senior Notes due 2032, $1.5B 5.450% Senior Notes due 2035.
July 31, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

CVS Health Q2 adj EPS $1.81; raises FY25 adj EPS outlook to $6.30-6.40, cuts GAAP view on litigation charges

Q2 revenue $98.9B (+8.4% YoY); GAAP EPS $0.80 vs $1.41; adj EPS $1.81 vs $1.83.
May 20, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

CVS Health annual meeting results: all 13 directors elected; say-on-pay passes with 59% support

All 13 director nominees elected; votes ranged from 926M to 1.007B in favor, with broker non-votes of 111M.
May 1, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

CVS Health Q1 Adj EPS $2.25 vs $1.31 YoY; raises FY25 Adj EPS guidance to $6.00-$6.20

Total revenues $94.6B, up 7.0% YoY; GAAP diluted EPS $1.41, Adjusted EPS $2.25.
April 8, 2025, 7:59 PM ET other material materiality 0.75 positive item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

CVS Health appoints new CFO and CMO; affirms FY2025 guidance will meet or exceed

Brian Newman named EVP & CFO effective May 12; base salary $1M, target bonus 150% of salary.
February 12, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

CVS Health Q4 revenue up 4.2% to $97.7B, adjusted EPS falls 44% to $1.19; FY25 guidance below consensus

GAAP diluted EPS $1.30 (down $0.28 YoY); adjusted EPS $1.19 (down $0.93 YoY) on Health Care Benefits weakness.
December 17, 2024, 6:59 PM ET debt materiality 0.50 neutral item 8.01 item 9.01

CVS Health announces early results and pricing of $1.774B debt tender offer; early settlement Dec 18

Maximum tender amount $1.774B; notes tendered exceeded cap; no further purchases expected after Dec 18.
December 10, 2024, 6:59 PM ET debt materiality 0.65 neutral item 8.01 item 9.01

CVS Health issues $3.0B in junior subordinated notes across two tranches

Issued $2.25B of 7.000% Fixed-to-Fixed Rate Series A Junior Subordinated Notes due 2055.
December 9, 2024, 6:59 PM ET debt materiality 0.40 neutral item 8.01 item 9.01

CVS Health completes tender offer for $226M of 4.100% Senior Notes due 2025

Tendered $225,979,000 principal amount of 4.100% Senior Notes due 2025 (out of $950,087,000 outstanding) plus $5,000 via guaranteed delivery.
December 6, 2024, 6:59 PM ET debt materiality 0.50 neutral item 8.01 item 9.01

CVS Health prices tender offer for $950M 4.100% Senior Notes due Mar 2025

Principal outstanding $950,087,000 of 4.100% Senior Notes due March 25, 2025.
December 5, 2024, 6:59 PM ET debt materiality 0.55 neutral item 8.01 item 9.01

CVS Health issues $3B junior subordinated notes: 7.0% due 2055, 6.75% due 2054

Issued $2.25B of 7.000% Series A Junior Subordinated Notes due 2055 and $750M of 6.750% Series B Junior Subordinated Notes due 2054.
December 2, 2024, 6:59 PM ET debt materiality 0.65 neutral item 8.01 item 9.01

CVS Health launches cash tender offers for up to $2B of senior notes; any and all 2025 notes included

Any and all tender for $950M 4.100% Senior Notes due 2025; fixed spread +25 bps over 3.875% UST due 3/31/2025.
November 18, 2024, 6:59 PM ET other material materiality 0.70 positive item 1.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×4

CVS Health adds four directors, enters pact with Glenview Capital; CEO pay raised

Board expanded from 12 to 16 with appointments of Leslie Norwalk, Larry Robbins, Guy Sansone, Doug Shulman.
November 6, 2024, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

CVS Health Q3 GAAP EPS $0.07, Adjusted EPS $1.09; records $1.1B premium deficiency reserve

Total revenues $95.4B (+6.3% YoY); GAAP diluted EPS $0.07 vs $1.75 prior year.
November 6, 2024, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

CVS Health appoints Prem Shah as Group President and Steve Nelson as President of Aetna

Prem Shah named EVP & Group President, overseeing CVS Caremark, CVS Pharmacy, and Health Care Delivery (Oak Street, Signify).
October 18, 2024, 7:59 PM ET leadership materiality 0.85 negative item 2.02 item 7.01 item 5.02 item 9.01 ◈ executive_change ×3

David Joyner named CVS Health CEO replacing Karen Lynch; preliminary Q3 EPS guide weak

David Joyner appointed President and CEO effective Oct. 17, 2024, succeeding Karen Lynch who resigned.
August 7, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

CVS Health Q2 adj EPS $1.83 vs $2.21 YoY; cuts FY2024 adj EPS guidance to $6.40-$6.65

Total revenues $91.2B, up 2.6% YoY; GAAP diluted EPS $1.41 vs $1.48, Adjusted EPS $1.83 vs $2.21.
May 22, 2024, 7:59 PM ET other materiality 0.50 neutral item 5.02 item 5.07 item 9.01

CVS shareholders approve 33.5M share increase to equity plan; all directors elected

Shareholders approved amendment to 2017 ICP, increasing authorized shares by 33.5 million for future awards.
May 9, 2024, 7:59 PM ET debt materiality 0.50 neutral item 8.01 item 9.01

CVS Health issues $5B in senior notes across five tranches with rates 5.400%-6.050%

Issued $1B at 5.400% due 2029, $1B at 5.550% due 2031, $1.25B at 5.700% due 2034.
May 8, 2024, 7:59 PM ET debt materiality 0.55 neutral item 8.01 item 9.01

CVS Health issues $5.0B in senior notes across five tranches with rates 5.4%-6.05%

Aggregate principal $5.0B; net proceeds ~$4.95B after underwriting discounts and expenses.
May 1, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

CVS Health Q1 GAAP EPS $0.88 vs $1.65; FY2024 guidance slashed on Medicare pressure

Q1 revenues rose 3.7% to $88.4B; GAAP diluted EPS $0.88 vs $1.65; adjusted EPS $1.31 vs $2.20.
March 5, 2024, 6:59 PM ET other material materiality 0.30 neutral item 7.01

CVS Health reiterates FY2024 guidance: GAAP EPS ≥$7.06, adjusted ≥$8.30

Reaffirmed FY2024 GAAP diluted EPS guidance of at least $7.06.
February 7, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

CVS Q4 revenue $93.8B (+11.9% YoY), adj. EPS $2.12; FY2024 adj. EPS guidance cut to $8.30

Q4 total revenues $93.8B (+11.9% YoY); GAAP diluted EPS $1.58, adjusted EPS $2.12.
January 5, 2024, 6:59 PM ET leadership materiality 0.65 positive item 2.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

CVS names Tom Cowhey CFO, Mike Pykosz President of Health Care Delivery; reaffirms FY2023 and FY2024 guidance

Thomas F. Cowhey appointed EVP and CFO effective Jan 5, 2024; receives $1M base salary, target cash incentive 150%, and $5.5M equity award.
December 5, 2023, 6:59 PM ET other materiality 0.75 positive item 7.01 item 9.01

CVS Health initiates FY24 guidance of at least $8.50 adj EPS, raises dividend 10%

Introduces CVS CostVantage and CVS Caremark TrueCost for transparent pharmacy reimbursement, launch in 2025.
November 1, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

CVS Health Q3 revenue $89.8B (+10.6%), GAAP EPS $1.75, Adj EPS $2.21, FY GAAP EPS guidance revised to $6.37-$6.61

Total revenues $89.8B, up 10.6% YoY; GAAP diluted EPS $1.75 vs loss of $2.59 prior year.
October 16, 2023, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

CVS CFO Shawn Guertin takes leave; Tom Cowhey named interim CFO; Mike Pykosz interim Health Svcs Pres

Guertin's leave effective immediately for unforeseen family medical reasons; Cowhey (SVP Corporate Finance) appointed interim CFO.
October 13, 2023, 7:59 PM ET regulatory materiality 0.65 positive item 7.01 item 9.01

87% of Aetna Medicare Advantage members now in 4+ Star plans for 2024; recovers majority of 2025 revenue headwind

Aetna National PPO improved from 3.5 to 4.0 Stars, driving increase from 21% to 87% of members in 4+ Star plans.
September 21, 2023, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

CVS Health elects Boston Scientific CEO Michael F. Mahoney to board

Michael F. Mahoney elected to CVS Health Board, effective November 1, 2023.
September 11, 2023, 7:59 PM ET earnings materiality 0.20 neutral item 7.01

CVS Health reaffirms FY2023 GAAP EPS $6.53-$6.75, Adjusted EPS $8.50-$8.70, CFO $12.5B-$13.5B

Reaffirms FY2023 GAAP diluted EPS range $6.53–$6.75, unchanged from prior guidance.
August 23, 2023, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

CVS Health launches Cordavis subsidiary; first biosimilar Hyrimoz at >80% lower list price than Humira

Launched Cordavis, a wholly owned subsidiary to commercialize and co-produce biosimilar products in the U.S.
August 17, 2023, 7:59 PM ET other material materiality 0.35 negative item 7.01

Blue Shield of California to drop CVS Caremark as PBM except specialty; CVS reaffirms 2023 guidance

Blue Shield of California will use multiple pharmacy providers starting 2024; CVS Caremark retained only for specialty pharmacy.
August 2, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

CVS Health Q2 rev +10%, EPS $1.48; lowers GAAP EPS guidance to $6.53-$6.75

Revenue $88.9B, +10.3% YoY; GAAP diluted EPS $1.48 (down from $2.29); adj EPS $2.21 (down from $2.53).
July 20, 2023, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

CVS Health elects United Airlines CEO J. Scott Kirby to board, effective Oct 1, 2023

J. Scott Kirby, CEO of United Airlines (UAL), elected to CVS Health Board effective October 1, 2023.
June 2, 2023, 7:59 PM ET debt materiality 0.50 neutral item 8.01 item 9.01

CVS Health issues $5B in senior notes across five tranches, 2029-2063 maturities

Issued $1B of 5.000% Senior Notes due 2029, $750M of 5.250% Notes due 2031.
June 1, 2023, 7:59 PM ET debt materiality 0.55 neutral item 8.01 item 9.01

CVS Health to issue $5B in senior notes across five tranches

Aggregate principal: $1B 5.000% notes due 2029, $750M 5.250% notes due 2031, $1.25B 5.300% notes due 2033, $1.25B 5.875% notes due 2053, $750M 6.000% notes due 2063.
May 31, 2023, 7:59 PM ET other material materiality 0.35 neutral item 7.01

CVS Health reaffirms FY2023 GAAP EPS $6.90-$7.12 and Adj. EPS $8.50-$8.70

Reaffirms full-year 2023 GAAP diluted EPS guidance range of $6.90 to $7.12.
May 25, 2023, 7:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

CVS Health 8-K contains XBRL data only; no material event discernible

Filing includes only XBRL-tagged financial data; no press release or narrative attachment.
May 24, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×9

CVS Health shareholders elect all 11 board nominees, approve E&Y, reject all five stockholder proposals

All 11 director nominees elected; Karen S. Lynch received ~922M for vs ~10.9M against.
May 3, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

CVS Health Q1 revenue up 11% to $85.3B; EPS falls; guidance cut; closes Signify & Oak Street

Total revenues $85.3B (+11% YoY); GAAP diluted EPS $1.65 (down from $1.77); Adjusted EPS $2.20 (down from $2.30).

Executive changes

Appointed

Teresa Heitsenrether

Director

CVS · CVS HEALTH Corp

Effective: 2026-11-18
Filed: August 17, 2026, 4:19 PM ET

On August 17, 2026, the Board appointed Teresa Heitsenrether to the Board, effective November 18, 2026.

Departed

Larry M. Robbins

Director

CVS · CVS HEALTH Corp

Effective: 2026-08-13
Filed: August 17, 2026, 4:19 PM ET

On August 13, 2026, Larry M. Robbins notified the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) of his resignation from the Board, effective immediately.

Role change

Thomas F. Cowhey

Executive Vice President and Chief Financial Officer

CVS · CVS HEALTH Corp

Effective: 2025-05-12
Filed: April 8, 2025, 7:59 PM ET

On April 7, 2025, the Board of Directors of the Company also determined that Thomas F. Cowhey, currently the Executive Vice President and Chief Financial Officer of CVS Health, will cease to serve as Executive Vice President and Chief Financial Officer of CVS Health as of the Effective Date.

Appointed

Brian O. Newman

Executive Vice President and Chief Financial Officer

CVS · CVS HEALTH Corp

Effective: 2025-05-12
Successor: Brian O. Newman
Filed: April 8, 2025, 7:59 PM ET

On April 7, 2025, the Board of Directors of CVS Health Corporation (the “Company” or “CVS Health”) appointed Brian O. Newman to serve as Executive Vice President and Chief Financial Officer of CVS Health, effective May 12, 2025 (the “Effective Date”).

Appointed

Larry Robbins

Director

CVS · CVS HEALTH Corp

Effective: 2024-11-17
Filed: November 18, 2024, 6:59 PM ET

On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.

Appointed

Doug Shulman

Director

CVS · CVS HEALTH Corp

Effective: 2024-11-17
Filed: November 18, 2024, 6:59 PM ET

On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.

Appointed

Guy Sansone

Director

CVS · CVS HEALTH Corp

Effective: 2024-11-17
Filed: November 18, 2024, 6:59 PM ET

On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.

Appointed

Leslie Norwalk

Director

CVS · CVS HEALTH Corp

Effective: 2024-11-17
Filed: November 18, 2024, 6:59 PM ET

On November 17, 2024, Ms. Norwalk, Mr. Robbins, Mr. Sansone and Mr. Shulman were appointed to the Board.

Appointed

Prem S. Shah

Executive Vice President and Group President

CVS · CVS HEALTH Corp

Effective: 2024-11-06
Filed: November 6, 2024, 6:59 PM ET

On November 6, 2024, CVS Health Corporation (the “ Company ”) appointed Prem S. Shah as Executive Vice President and Group President, a newly created position within the Company.

Departed

Karen S. Lynch

President and Chief Executive Officer

CVS · CVS HEALTH Corp

Effective: 2024-10-17
Successor: J. David Joyner
Filed: October 18, 2024, 7:59 PM ET

Karen S. Lynch ceased to serve as President and Chief Executive Officer of the Company and resigned as a member of the Board on the same day.

Role change

Roger N. Farah

Executive Chairman of the Board

CVS · CVS HEALTH Corp

Effective: 2024-10-17
Filed: October 18, 2024, 7:59 PM ET

Effective October 17, 2024, the Board has also appointed current Chairman Roger N. Farah as Executive Chairman of the Board.

Appointed

J. David Joyner

President and Chief Executive Officer

CVS · CVS HEALTH Corp

Effective: 2024-10-17
Filed: October 18, 2024, 7:59 PM ET

the Board of Directors (the “ Board ”) of the Company appointed J. David Joyner as President and Chief Executive Officer of the Company, effective as of October 17, 2024.

Earnings & guidance

2026-Q2 EPS reported $4.61 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

12 positive 8 negative 30 neutral

source · CVS on sec.gov